Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 5, 2025International Journal of HematologyOpen Access

Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR)

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAtsushi� SatakeYNYasuhiro NagateKMKohta Miyawaki

Discussion

Loading...

Member takes

Overview

Observational analysis shows 95% response rate in untreated DLBCL patients, indicating promising safety for Pola-R-CHP treatment.

Key Points

  • Overall response rate reached 95.0% among 141 patients evaluated for efficacy at end of treatment.
  • Among 199 enrolled patients, 51.6% experienced Grade ≥ 3 adverse events, outlining important safety considerations.
  • Analysis based on real-world data from the POLASTAR study highlights treatment efficacy and safety in the Japanese population.
  • The study's results align with previously published data from POLARIX, emphasizing the consistency of Pola-R-CHP outcomes.

Cite This Study

Satake et al. (2025) studied this question.

synapsesocial.com/papers/6932313d8e51979591dcef2chttps://doi.org/10.1007/s12185-025-04122-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real‐World Safety and Efficacy of Pola‐R‐ <scp>CHP</scp> in Previously Untreated <scp>DLBCL</scp> : <scp>POLASTAR</scp> Interim Analysis of 500 Patients2026
  2. 2Patient characteristics and treatment outcomes with Pola-R-CHP: A real-world study of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in the United States (US)2025 · 2 citations
  3. 3A retrospective Study of pola-R-CHP regimen in treatment-naive patients with diffuse large B-cell lymphoma from northeast China2025
  4. 4Real-world use of Pola-R-CHP for untreated diffuse large B-cell lymphoma (DLBCL): A systematic literature review2025
  5. 5Pola-R-CHP in newly diagnosed primary mediastinal B-cell lymphoma:high efficacy and tolerability2025